



GlycoExpress®

Toolbox for High Yield Production of Human Glyco-Optimized Biopharmaceuticals

The expression of human protein-based biopharmaceuticals requires a biological system closely resembling its human origin. Thus, proper glycosylation, a key feature of biotherapeutics, strongly influences bioactivity, solubility, stability, serum half-life, and immunogenicity.

FyoniBio offers **GlycoExpress® (GEX®)** — a well-established and extensively characterized human screening and expression technology platform suitable for a broad range of proteins.

GEX® contains proprietary glyco-optimized human cell lines designed for the development and production of biotherapeutics with authentic human-optimized glycosylation patterns, ensuring no immunogenic, non-human carbohydrate residues.

Our platform manufacturing process ensures reliable outcomes, stable product quality, especially in glycosylation, and minimized batch-to-batch variations. Additionally, we achieve high productivity for glyco-optimized products.




With GEX®, we can modify and control post-translational modifications, with glycosylation being our main expertise among others.

Our GlycoExpress® Platform:

- **SialoMax:** for high sialylation and high core fucosylation
- **SialoFlex:** for adjusting sialylation
- **FucoFlex:** for adjusting fucosylation
- **ManFlex:** for mannose-6-phosphate adjustment


GlycoExpress® is approved by the **FDA**, **EMA**, and German regulatory authorities, including the **PEI** and **BfArM**, for the manufacturing of biopharmaceuticals.

Explore our Broad Toolbox of Glyco-Optimized Cell Lines



Expression Platform for Different Biopharmaceuticals

- Complex antibody isotypes (e.g., IgA and IgM)
- Difficult-to-express and complex glycosylated proteins (e.g. rhSP-D and others)
- Blood factors (e.g., FVII)
- Protein hormones (e.g., FSH, HCG)
- Fusion proteins with extended serum half-life
- Enzymes (e.g., for enzyme replacement therapy)



Further glyco-optimized cell lines are continuously being developed to meet individual product requirements.

Preclinical Manufacturing of Protein Biopharmaceuticals

FyoniBio provides preclinical CMC services for your biopharmaceutical products:

- Cell line development using the most suitable GEX® cell line
- Bioprocess development (USP) in perfusion or intensified fed-batch mode
- Protein purification and downstream processing (DSP)
- Bioactivity assays
- PTM analytics

Yields for Selected Product Types

Product Class	Productivity
IgA*	10-15 g/l
Glycoprotein*	4 g/l
IgM*	3 g/l
Complex glycoprotein**	1 g/l

*In a 40 days of perfusion run

**in a 6 days of intensified fed-batch run

The FyoniBio Team Is All Set to Bring Your CMC Project to the Next Level!

FyoniBio offers high quality ISO-9001 compliant services. For more information please contact us.



FyoniBio GmbH
www.fyonibio.com

Robert-Roessle-Str. 10
13125 Berlin, Germany

+49 (0) 30 9489 2500
contact@fyonibio.com

